RxDoctor Payments Data

Suzan Parks, APRN

Family · Norman, OKNPI 1720713340

Payments from drug & device makers

$1,398in general payments, 2019–2025

Across 70 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$365
  • AstraZeneca$216
  • Otsuka America Pharmaceutical, Inc.$164
  • Novo Nordisk$134
  • Lilly USA, LLC$108
  • Amgen$87
  • plus $324 from 11 others

What the payments were for

  • Food & beverage$1,398100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,398 in reported general payments places this provider in the 75th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$25,051
Medicare patients
146
Services billed
512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide26$28,852
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$23,481
OzempicSemaglutide16$18,345
SynthroidLevothyroxine Sodium13$1,406
Atorvastatin Calcium87$1,000
Albuterol Sulfate HfaAlbuterol Sulfate30$869
Montelukast Sodium24$785
Levothyroxine Sodium81$742
Celecoxib20$694
Omeprazole43$681
Gabapentin32$589
Pantoprazole Sodium30$490
Bupropion XlBupropion Hcl16$352
Sertraline Hcl31$351
Losartan Potassium37$336

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$108$28,85226 claims
GSKTrelegy Ellipta$19$23,48137 claims
Novo NordiskOzempic$134$18,34516 claims
AbbVieSynthroid$365$1,40613 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$13$74281 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,026 family providers in Oklahoma.

Other family in Norman

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →